Emir Behluli

Emir Behluli

Auto-generated profile, based on publicly available information

Emir Behluli

Departments of Pediatrics, University of Pristina Medical Faculty, Pristina, Kosovo

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Folia Medica
Verified
Journal Article
Open access
PDF file
EBEmir Behluli
Emir Behluli
LSLidvana Spahiu
Lidvana Spahiu
VIVlora Ismaili-jaha
Vlora Ismaili-jaha
BNBurim Neziri
Burim Neziri
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
Introduction: Many authors in their research have suggested an association between vitamin D and asthma, but the results from these publications are sometimes confusing. Aim: Our aim was to assess the relationship between serum vitamin D and lung function in patients previously diagnosed with asthma. Materials and methods: The present study started in September 2019 and was completed in May 2020. All patients were diagnosed at the University Clinical Center-Prishtina, Kosovo. Spirometry was performed on children of ages 6-16 years old with a spirometer according to the recommendations of the American Thoracic Society. Results: Of the 57 children who visited the University Clinical Center of Kosovo-Department of Pediatrics, 29 were diagnosed with asthma. The Spearman coefficient correlation showed statistical significance between vitamin D and body weight, and vitamin D and FEF75% at level 0.05. Other parameters did not show statistical significance with vitamin D, but such statistical significance was found in other parameters between asthma and healthy groups. Conclusions: Our data suggested that serum vitamin D level was insignificant for FVC%, FEV1%, Tiffeneau Index values, and PEF. Statistical significance was observed between vitamin D and body weight; vitamin D and FEF75% (p=0.05).

6 October 2023 in Pharmacia
Verified
Journal Article
Open access
PDF file
EBEmir Behluli
Emir Behluli
TLThomas Liehr
Thomas Liehr
RHRifat Hadžiselimović
Rifat Hadžiselimović
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
Systemic lupus erythematosus (SLE) is a disease associated with an impaired autoimmune response; the immune system attacks erroneously own tissues, which leads to inflammation, tissue damage and complement activation. The latter plays a pivotal role in SLE pathology, as complement level is suited as histological marker for disease diagnoses and management. Besides, environmentally factors have been highlighted and their significant contribution for individual genetic predisposition has been pointed out. Here complement factors, their activity and their ability to modify DNA with histone proteins are reviewed; known gene mutations involved in SLE, and new therapeutic approaches suggested for SLE are discussed and summarized, as well.

31 March 2025 in Current Issues in Pharmacy and Medical Sciences
Verified
Journal Article
Open access
PDF file
EBEmir Behluli
Emir Behluli
SXShefki Xharra
Shefki Xharra
HNHilada Nefic
Hilada Nefic
RHRifat Hadžiselimović
Rifat Hadžiselimović
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
The chemical reactive molecule ROS (Reactive Oxygen Species) is a product of normal cellular metabolism. ROS plays a pivotal role in a wide range of biological processes, including aging, cancer and neurodegenerative diseases. Recent studies have shown that ROS can also affect the ribosomes – molecular machines responsible for protein synthesis. ROS leads to errors in protein synthesis and the production of misfolded proteins, causing damage to ribosomes. However, it has also been suggested that ROS is implicated in the regulation of the ribosome activity under certain conditions. The aim of this paper is to review current knowledge regarding the effects of ROS on ribosomes, with a focus on the mechanisms by which ROS can cause damage to ribosomes and the potential role of ROS in regulating ribosome activity.

1 January 2022 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
STSkender Telaku
Skender Telaku
MTMimoza Telaku
Mimoza Telaku
EBEmir Behluli
Emir Behluli
VIViktor Isjanovski
Viktor Isjanovski
FAFitim Alidema
Fitim Alidema
Background/Objectives: To assess the effectiveness and safeness of Lactobacillus reuteri and additionally three other probiotics to conventional triple therapy against the Heliobacter pylori.Materials and Methods: We randomly selected 115 H. pylori positive dyspeptic patients, to be treated for 14 days with conventional triple therapy, without and with probiotics. Our first group of 62 patients received conventional triple therapy, while the second group of 53 patients were treated with Lactobacillus reuteri, and Lactobacillus casei, Lactobacillus acidophilus, Bifidobacterium lactis, all encapsulated in PharmaS Helicobalans capsules alongside the triple conventional therapy. One month after completion of treatment, Helicobacter pylori presence was evaluated. If the Helicobacter pylori test would turn out negative, it would prove the success of the eradication.Results: 38 patients of the first group (61,3%) were treated successfully. In the second group, where probiotics were added, the success of eradication was observed in 37 of them (69.8%).Despite the fact that eradication was higher in the second group, the difference between the two sides in terms of statistics was non-significant (p=0.199). As for the side effects of the ordered treatment, 27 patients of the first group (43.5%) had complaints, while the secondary group had 17(32%). Again, there was seen no difference statistically important between two sides.Conclusion: Including probiotics additionally to conventional Helicobacter pylori treatment may decrease the side effects of the therapy, and increase the Helicobacter pylori eradication success. Randomized prospective work on a larger scale is needed.

Verified
Open access
EBEmir Behluli
Emir Behluli
NNNexhibe Nuhii
Nexhibe Nuhii
Thomas LiehrThomas Liehr
Thomas Liehr
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
Children with Down syndrome (DS) are at markedly increased risk for acute lymphoblastic leukaemia (ALL). DS is caused by trisomy of chromosome 21 affecting approximately 1 in 732 newborns in the USA. ALL is the most common cancer in children and constitutes approximately 25% of cancer diagnoses among children under the age of 15. Different protocols for treatment and management of paediatric ALL are available; however, DS children with ALL (DS-ALL) have increased risk of therapy-related toxicity compared to those without DS. Herein, we summarize the available literature on inherited predisposition for ALL, and possibilities for molecular therapy and treatment for DS-ALL patients.

17 April 2024 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
VUVioleta Grajçevci Uka
Violeta Grajçevci Uka
EBEmir Behluli
Emir Behluli
RHRifat Hadžiselimović
Rifat Hadžiselimović
Thomas LiehrThomas Liehr
Thomas Liehr
Gazmend TEMAJGazmend TEMAJ
Gazmend TEMAJ
Introduction: Acute lymphoblastic leukemia (ALL) is the most frequent pediatric leukemia; it can be defined according to chromosomic and genomic data. Cytogenetic analyses and determination of chromosomal numbers (such as hypo- or hyperdiploidy) and/or specific chromosomal rearrangements are basic for ALL classification and treatment. Even though cure rates of childhood ALL are at ~95%, pharmacogenetic aspects are of raising importance. Material and Methods: We have analyzed the literature for ALL subtypes, corresponding therapy options, and pharmacogenetic implications. Results: Data for ALL subtypes such as B-ALL, T-ALL, Ph-like ALL, DS-ALL, ETP-ALL, BCR-ABL1-like ALL are presented here. The gene polymorphism which lead to metabolizability of 6-MP are ITPA variants (94C>A) and IVS2+21A>C, in conjunction with TPMT (238G>C, TPMT*3B 460G>A and *3C 719A>G and NUDT15 (415C>T). For methotrexate metabolism gene polymorphisms are found for gene MTHFR as C677T and A1298C. Conclusion: In the last decade in many hospital laboratories, pharmacogenetic aspects gain more and more importance. Application of many molecular biology methods provided progress in treatment and diagnosis of ALL patients. Combination therapy is proposed as an alternative to single drug treatments. Introduction: Acute lymphoblastic leukemia (ALL) is the most frequent pediatric leukemia; it can be defined according to chromosomic and genomic data. Cytogenetic analyses and determination of chromosomal numbers (such as hypo- or hyperdiploidy) and/or specific chromosomal rearrangements are basic for ALL classification and treatment. Even though cure rates of childhood ALL are at ~95%, pharmacogenetic aspects are of raising importance. Material and Methods: We have analyzed the literature for ALL subtypes, corresponding therapy options, and pharmacogenetic implications. Results: Data for ALL subtypes such as B-ALL, T-ALL, Ph-like ALL, DS-ALL, ETP-ALL, BCR-ABL1-like ALL are presented here. The gene polymorphism which lead to metabolizability of 6-MP are ITPA variants (94C>A) and IVS2+21A>C, in conjunction with TPMT (238G>C, TPMT*3B 460G>A and *3C 719A>G and NUDT15 (415C>T). For methotrexate metabolism gene polymorphisms are found for gene MTHFR as C677T and A1298C. Conclusion: In the last decade in many hospital laboratories, pharmacogenetic aspects gain more and more importance. Application of many molecular biology methods provided progress in treatment and diagnosis of ALL patients. Combination therapy is proposed as an alternative to single drug treatments.